Gilenya made revenues of $2.8 billion in 20021, with half of that total coming from the US market, although it has started to shrink as a result of increased competition in the market for ...

Novartis has released new data showing that its drug Gilenya benefited patients by improving all four key measures of multiple sclerosis (MS). Gilenya (fingolimod) is the first once-daily oral ...

A US court has ordered generic drug makers to stop selling a copy of Gilenya in US. The annual sales of Gilenya, a drug used to treat multiple sclerosis, was about $3.3 billion in 2018.